日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

作者更正:DKN-01 和替雷利珠单抗作为 DKK1 高表达胃食管腺癌二线治疗:DisTinGuish 试验 B 部分

Lee, Keun-Wook; Mahalingam, Devalingam; Shim, Byoung Yong; Kim, In-Ho; Oh, Do-Youn; Uronis, Hope; Sym, Sun Jin; Sonbol, Mohamad; Almhanna, Khaldoun; Tejani, Mohamedtaki A; Kang, Beodeul; Kagey, Michael H; Stilian, Melissa; Jia, Calvin; Sirard, Cynthia A; Altura, Rachel; Ajani, Jaffer A; Klempner, Samuel J

Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies

佐贝妥昔单抗联合化疗治疗患者恶心/呕吐的影响及有效管理:来自 III 期 SPOTLIGHT 和 GLOW 研究的启示

Shitara, K; Smyth, E; Lordick, F; Pophale, R; Matney, C; Matsangou, M; Gourgioti, G; Oh, M; Ranganath, R; Klempner, S J

Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers

循环肿瘤DNA可指导复发/转移性胃食管癌患者的临床实践

Mehta, Rutika; Rivero-Hinojosa, Samuel; Dayyani, Farshid; Ferguson, Jenifer; Shariff, Bushra; Aushev, Vasily N; Budde, Griffin L; Ortiz, J Bryce; George, Giby V; Sharma, Shruti; Jurdi, Adham A; Liu, Minetta C; Drengler, Ronald L; Klempner, Samuel J

Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors

Claudin 18.2 作为胃胰腺肿瘤影像学和放射性药物治疗的生物标志物

Raheem, Shvan J; Bashyal, Santosh; Haj-Mirzaian, Arvin; Khazaei Monfared, Yousef; Mahmood, Umar; Heidari, Pedram; Strickland, Matthew R; Ting, David T; Klempner, Samuel J; Larimer, Benjamin M; Esfahani, Shadi A

Clinicopathologic correlates of claudin 18.2 expression in esophagogastric cancer at multiple expression levels

食管胃癌中 Claudin 18.2 表达的临床病理相关性及多种表达水平

Maeng, C H; Alkashash, A; Sy, A; Barnes, H; Bannon, S; Simms, C; Strickland, M R; Glickman, J N; Klempner, S J

Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors

KRAS(G12C)抑制剂治疗患者临床获得性耐药性改变的基因组图谱

Riedl, J M; Fece de la Cruz, F; Lin, J J; Parseghian, C; Kim, J E; Matsubara, H; Barnes, H; Caughey, B; Norden, B L; Morales-Giron, A A; Kushner, E W; Ehnstrom, S; Nakamura, H; Patel, P S; Ellis, H; Pappas, L; Vakaris, A; Gainor, J F; Kopetz, S; Klempner, S J; Parikh, A R; Hata, A N; Heist, R S; Corcoran, R B

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

DKN-01联合替雷利珠单抗和化疗作为晚期胃癌或胃食管交界处腺癌的一线治疗:DisTinGuish

Klempner, Samuel J; Sonbol, Mohamad Bassam; Wainberg, Zev A; Uronis, Hope Elizabeth; Chiu, Vi K; Scott, Aaron James; Iqbal, Syma; Tejani, Mohamedtaki Abdulaziz; Chung, Vincent; Stilian, Melissa C; Thoma, Mathis; Zhang, Ying; Kagey, Michael H; Baum, Jason; Sirard, Cynthia A; Altura, Rachel A; Ajani, Jaffer A

Apples, Oranges, and ESOPEC Recurrence Patterns

苹果、橘子和ESOPEC复发模式

Strickland, Matthew R; Hong, Theodore S; Klempner, Samuel J

Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies

对靶向 Claudin 18.2 的免疫疗法的靶内/脱靶毒性进行建模和分析

Carstens, Elizabeth J; Takahashi, Kazuki; Sakamoto, Naoya; De Vizio, Martina; Morgado, Micaela; Nikkhoi, Shahryar Khoshtinat; Mangipudi, Abhishek; Nguyen, Canh Hiep; Weltzin, Tate; Nakayama, Izuma; Lv, Qiang; Zeng, Jue; Nie, Cui; Deng, Changjing; Wang, Xiaoxiao; Liu, Lile; Klempner, Samuel J; Ramasubramanian, Anusuya; Nowak, Jonathan A; Aguirre, Andrew J; Shitara, Kohei; Smith, Eric L

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

DKN-01 和替雷利珠单抗作为 DKK1 高表达胃食管腺癌的二线治疗:DisTinGuish 试验 B 部分

Lee, Keun-Wook; Mahalingam, Devalingam; Shim, Byoung Yong; Kim, In-Ho; Oh, Do-Youn; Uronis, Hope; Sym, Sun Jin; Sonbol, Mohamad; Almhanna, Khaldoun; Tejani, Mohamedtaki A; Kang, Beodeul; Kagey, Michael H; Stilian, Melissa; Jia, Calvin; Sirard, Cynthia A; Altura, Rachel; Ajani, Jaffer A; Klempner, Samuel J